Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Glucagon-like Peptide-1 Receptor Agonist Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Exenatide
1.2.3 Liraglutide
1.2.4 Lixisenatide
1.2.5 Albiglutide
1.2.6 Others
1.3 Market by Application
1.3.1 Global Glucagon-like Peptide-1 Receptor Agonist Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Solid Tumors
1.3.3 Blood-related Tumors
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Glucagon-like Peptide-1 Receptor Agonist Market Perspective (2018-2033)
2.2 Glucagon-like Peptide-1 Receptor Agonist Growth Trends by Region
2.2.1 Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Glucagon-like Peptide-1 Receptor Agonist Historic Market Size by Region (2018-2023)
2.2.3 Glucagon-like Peptide-1 Receptor Agonist Forecasted Market Size by Region (2024-2033)
2.3 Glucagon-like Peptide-1 Receptor Agonist Market Dynamics
2.3.1 Glucagon-like Peptide-1 Receptor Agonist Industry Trends
2.3.2 Glucagon-like Peptide-1 Receptor Agonist Market Drivers
2.3.3 Glucagon-like Peptide-1 Receptor Agonist Market Challenges
2.3.4 Glucagon-like Peptide-1 Receptor Agonist Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Glucagon-like Peptide-1 Receptor Agonist Players by Revenue
3.1.1 Global Top Glucagon-like Peptide-1 Receptor Agonist Players by Revenue (2018-2023)
3.1.2 Global Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Players (2018-2023)
3.2 Global Glucagon-like Peptide-1 Receptor Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Glucagon-like Peptide-1 Receptor Agonist Revenue
3.4 Global Glucagon-like Peptide-1 Receptor Agonist Market Concentration Ratio
3.4.1 Global Glucagon-like Peptide-1 Receptor Agonist Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Glucagon-like Peptide-1 Receptor Agonist Revenue in 2022
3.5 Glucagon-like Peptide-1 Receptor Agonist Key Players Head office and Area Served
3.6 Key Players Glucagon-like Peptide-1 Receptor Agonist Product Solution and Service
3.7 Date of Enter into Glucagon-like Peptide-1 Receptor Agonist Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Glucagon-like Peptide-1 Receptor Agonist Breakdown Data by Type
4.1 Global Glucagon-like Peptide-1 Receptor Agonist Historic Market Size by Type (2018-2023)
4.2 Global Glucagon-like Peptide-1 Receptor Agonist Forecasted Market Size by Type (2024-2033)
5 Glucagon-like Peptide-1 Receptor Agonist Breakdown Data by Application
5.1 Global Glucagon-like Peptide-1 Receptor Agonist Historic Market Size by Application (2018-2023)
5.2 Global Glucagon-like Peptide-1 Receptor Agonist Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Glucagon-like Peptide-1 Receptor Agonist Market Size (2018-2033)
6.2 North America Glucagon-like Peptide-1 Receptor Agonist Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Glucagon-like Peptide-1 Receptor Agonist Market Size by Country (2018-2023)
6.4 North America Glucagon-like Peptide-1 Receptor Agonist Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Glucagon-like Peptide-1 Receptor Agonist Market Size (2018-2033)
7.2 Europe Glucagon-like Peptide-1 Receptor Agonist Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Glucagon-like Peptide-1 Receptor Agonist Market Size by Country (2018-2023)
7.4 Europe Glucagon-like Peptide-1 Receptor Agonist Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Market Size (2018-2033)
8.2 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Market Size by Region (2018-2023)
8.4 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Glucagon-like Peptide-1 Receptor Agonist Market Size (2018-2033)
9.2 Latin America Glucagon-like Peptide-1 Receptor Agonist Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Glucagon-like Peptide-1 Receptor Agonist Market Size by Country (2018-2023)
9.4 Latin America Glucagon-like Peptide-1 Receptor Agonist Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Market Size (2018-2033)
10.2 Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Market Size by Country (2018-2023)
10.4 Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK Glucagon-like Peptide-1 Receptor Agonist Introduction
11.1.4 GSK Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023)
11.1.5 GSK Recent Development
11.2 Novo Nordisk
11.2.1 Novo Nordisk Company Detail
11.2.2 Novo Nordisk Business Overview
11.2.3 Novo Nordisk Glucagon-like Peptide-1 Receptor Agonist Introduction
11.2.4 Novo Nordisk Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023)
11.2.5 Novo Nordisk Recent Development
11.3 Lily
11.3.1 Lily Company Detail
11.3.2 Lily Business Overview
11.3.3 Lily Glucagon-like Peptide-1 Receptor Agonist Introduction
11.3.4 Lily Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023)
11.3.5 Lily Recent Development
11.4 Haosoh
11.4.1 Haosoh Company Detail
11.4.2 Haosoh Business Overview
11.4.3 Haosoh Glucagon-like Peptide-1 Receptor Agonist Introduction
11.4.4 Haosoh Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023)
11.4.5 Haosoh Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Glucagon-like Peptide-1 Receptor Agonist Introduction
11.5.4 Sanofi Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023)
11.5.5 Sanofi Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Detail
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Glucagon-like Peptide-1 Receptor Agonist Introduction
11.6.4 AstraZeneca Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023)
11.6.5 AstraZeneca Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Glucagon-like Peptide-1 Receptor Agonist Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Exenatide
Table 3. Key Players of Liraglutide
Table 4. Key Players of Lixisenatide
Table 5. Key Players of Albiglutide
Table 6. Key Players of Others
Table 7. Global Glucagon-like Peptide-1 Receptor Agonist Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 9. Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Glucagon-like Peptide-1 Receptor Agonist Market Share by Region (2018-2023)
Table 11. Global Glucagon-like Peptide-1 Receptor Agonist Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 12. Global Glucagon-like Peptide-1 Receptor Agonist Market Share by Region (2024-2033)
Table 13. Glucagon-like Peptide-1 Receptor Agonist Market Trends
Table 14. Glucagon-like Peptide-1 Receptor Agonist Market Drivers
Table 15. Glucagon-like Peptide-1 Receptor Agonist Market Challenges
Table 16. Glucagon-like Peptide-1 Receptor Agonist Market Restraints
Table 17. Global Glucagon-like Peptide-1 Receptor Agonist Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Glucagon-like Peptide-1 Receptor Agonist Market Share by Players (2018-2023)
Table 19. Global Top Glucagon-like Peptide-1 Receptor Agonist Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon-like Peptide-1 Receptor Agonist as of 2022)
Table 20. Ranking of Global Top Glucagon-like Peptide-1 Receptor Agonist Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Glucagon-like Peptide-1 Receptor Agonist Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Glucagon-like Peptide-1 Receptor Agonist Product Solution and Service
Table 24. Date of Enter into Glucagon-like Peptide-1 Receptor Agonist Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Type (2018-2023)
Table 28. Global Glucagon-like Peptide-1 Receptor Agonist Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 29. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Type (2024-2033)
Table 30. Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Application (2018-2023)
Table 32. Global Glucagon-like Peptide-1 Receptor Agonist Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 33. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Application (2024-2033)
Table 34. North America Glucagon-like Peptide-1 Receptor Agonist Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. North America Glucagon-like Peptide-1 Receptor Agonist Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Glucagon-like Peptide-1 Receptor Agonist Market Size by Country (2024-2033) & (US$ Million)
Table 37. Europe Glucagon-like Peptide-1 Receptor Agonist Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 38. Europe Glucagon-like Peptide-1 Receptor Agonist Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Glucagon-like Peptide-1 Receptor Agonist Market Size by Country (2024-2033) & (US$ Million)
Table 40. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 41. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Market Size by Region (2024-2033) & (US$ Million)
Table 43. Latin America Glucagon-like Peptide-1 Receptor Agonist Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Latin America Glucagon-like Peptide-1 Receptor Agonist Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Glucagon-like Peptide-1 Receptor Agonist Market Size by Country (2024-2033) & (US$ Million)
Table 46. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 47. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Market Size by Country (2024-2033) & (US$ Million)
Table 49. GSK Company Detail
Table 50. GSK Business Overview
Table 51. GSK Glucagon-like Peptide-1 Receptor Agonist Product
Table 52. GSK Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023) & (US$ Million)
Table 53. GSK Recent Development
Table 54. Novo Nordisk Company Detail
Table 55. Novo Nordisk Business Overview
Table 56. Novo Nordisk Glucagon-like Peptide-1 Receptor Agonist Product
Table 57. Novo Nordisk Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023) & (US$ Million)
Table 58. Novo Nordisk Recent Development
Table 59. Lily Company Detail
Table 60. Lily Business Overview
Table 61. Lily Glucagon-like Peptide-1 Receptor Agonist Product
Table 62. Lily Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023) & (US$ Million)
Table 63. Lily Recent Development
Table 64. Haosoh Company Detail
Table 65. Haosoh Business Overview
Table 66. Haosoh Glucagon-like Peptide-1 Receptor Agonist Product
Table 67. Haosoh Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023) & (US$ Million)
Table 68. Haosoh Recent Development
Table 69. Sanofi Company Detail
Table 70. Sanofi Business Overview
Table 71. Sanofi Glucagon-like Peptide-1 Receptor Agonist Product
Table 72. Sanofi Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023) & (US$ Million)
Table 73. Sanofi Recent Development
Table 74. AstraZeneca Company Detail
Table 75. AstraZeneca Business Overview
Table 76. AstraZeneca Glucagon-like Peptide-1 Receptor Agonist Product
Table 77. AstraZeneca Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023) & (US$ Million)
Table 78. AstraZeneca Recent Development
Table 79. Research Programs/Design for This Report
Table 80. Key Data Information from Secondary Sources
Table 81. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Glucagon-like Peptide-1 Receptor Agonist Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Glucagon-like Peptide-1 Receptor Agonist Market Share by Type: 2022 VS 2033
Figure 3. Exenatide Features
Figure 4. Liraglutide Features
Figure 5. Lixisenatide Features
Figure 6. Albiglutide Features
Figure 7. Others Features
Figure 8. Global Glucagon-like Peptide-1 Receptor Agonist Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 9. Global Glucagon-like Peptide-1 Receptor Agonist Market Share by Application: 2022 VS 2033
Figure 10. Solid Tumors Case Studies
Figure 11. Blood-related Tumors Case Studies
Figure 12. Glucagon-like Peptide-1 Receptor Agonist Report Years Considered
Figure 13. Global Glucagon-like Peptide-1 Receptor Agonist Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 14. Global Glucagon-like Peptide-1 Receptor Agonist Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 15. Global Glucagon-like Peptide-1 Receptor Agonist Market Share by Region: 2022 VS 2033
Figure 16. Global Glucagon-like Peptide-1 Receptor Agonist Market Share by Players in 2022
Figure 17. Global Top Glucagon-like Peptide-1 Receptor Agonist Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon-like Peptide-1 Receptor Agonist as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Glucagon-like Peptide-1 Receptor Agonist Revenue in 2022
Figure 19. North America Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. North America Glucagon-like Peptide-1 Receptor Agonist Market Share by Country (2018-2033)
Figure 21. United States Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Canada Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Glucagon-like Peptide-1 Receptor Agonist Market Share by Country (2018-2033)
Figure 25. Germany Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. France Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. U.K. Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Italy Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Russia Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Nordic Countries Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Market Share by Region (2018-2033)
Figure 33. China Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Japan Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. South Korea Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Southeast Asia Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. India Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Australia Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Glucagon-like Peptide-1 Receptor Agonist Market Share by Country (2018-2033)
Figure 41. Mexico Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Brazil Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Market Share by Country (2018-2033)
Figure 45. Turkey Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Saudi Arabia Glucagon-like Peptide-1 Receptor Agonist Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. GSK Revenue Growth Rate in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023)
Figure 48. Novo Nordisk Revenue Growth Rate in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023)
Figure 49. Lily Revenue Growth Rate in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023)
Figure 50. Haosoh Revenue Growth Rate in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023)
Figure 51. Sanofi Revenue Growth Rate in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023)
Figure 52. AstraZeneca Revenue Growth Rate in Glucagon-like Peptide-1 Receptor Agonist Business (2018-2023)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed